Delivery Order SPE2DB20D3101-SPE2DB25FRUX5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,040.63 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100 100s, a pharmaceutical product used for malaria prophylaxis and treatment. The contract, awarded on September 2, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $1,100.20 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Atovaquone-Proguanil 250-100 (100 tablets). This is a firm fixed-price delivery order with no set-aside designation, demonstrating that the award was competitively procured. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 30, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,586.54 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 tablets in a quantity of 100 units. This is a firm fixed price, competitively awarded delivery order with an ultimate completion date of September 11, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The product being...
- The Defense Logistics Agency awarded a delivery order valued at $22,857.87 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100mg tablets (100 count). This competitive, non-set-aside contract utilizes firm fixed pricing and carries an ultimate completion date of July 21, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. The medication is an...
- The Defense Logistics Agency awarded a delivery order valued at $1,117.35 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100 count) with an ultimate completion date of August 25, 2025. This firm fixed price, non-set-aside contract was awarded on August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The antimalarial medication will support federal medical supply requirements, likely for military personnel...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $111,930.00 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 mg tablets (100-count packages) with a firm fixed price structure. The contract, which was competitively awarded without set-aside designation, has an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,245.97 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 (100 tablets), a antimalarial medication used primarily for malaria prophylaxis and treatment in military personnel. The contract was awarded on August 7, 2025, with an ultimate completion date of August 8, 2025, under firm fixed price terms with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,119.30 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The antimalarial pharmaceutical is being procured through the...
- The Defense Logistics Agency (DLA) awarded a $31,675.49 firm fixed price delivery order to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100 count). This contract, awarded on September 2, 2025, with an ultimate completion date of September 3, 2025, represents a pharmaceutical supply delivery under a non-set-aside competitive procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order valued at $3,469.83 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Atovaquone-Proguanil 250-100mg in 100-count units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 8, 2025, performed at the contractor's facility in Conshohocken, Pennsylvania. The antimalarial medication delivery supports federal medical procurement requirements, particularly for military and veteran...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRUX5Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,343.16 on September 9, 2025, for Atovaquone-Proguanil 250-100 (100 tablets), with a completion date of September 10, 2025. This is a firm fixed-price delivery order under a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical supply needs. The order represents a child contract under the company's broader relationship with the DLA. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle providing a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Atovaquone-Proguanil is an antimalarial medication commonly used for malaria prophylaxis and treatment in military and veteran healthcare systems, reflecting the company's role in supplying specialized medical commodities across multiple therapeutic domains to the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 9/9/25 |